Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 103; no. 1; pp. e1 - e4
Main Authors Botzenhardt, Sebastian, Felisi, Mariagrazia, Bonifazi, Donato, Del Vecchio, Giovanni C, Putti, Maria C, Kattamis, Antonis, Ceci, Adriana, Wong, Ian C K, Neubert, Antje
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.01.2018
Subjects
Age Factors
beta-Thalassemia - complications
beta-Thalassemia - diagnosis
beta-Thalassemia - therapy
Child
Deferiprone - administration & dosage
Deferiprone - adverse effects
Deferiprone - therapeutic use
Humans
Iron Chelating Agents - administration & dosage
Iron Chelating Agents - adverse effects
Iron Chelating Agents - therapeutic use
Iron Overload - diagnosis
Iron Overload - drug therapy
Iron Overload - etiology
Mediterranean Region
Online Only
Treatment Outcome
Mediterranean Region
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Undefined-3
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2017.176065